# LABORATORY CORP OF AMERICA HOLDINGS

Summary updated: 2026-10-02T08:58:37.616168Z
Canonical: https://finbar.com/research/companies/laboratory-of-america-holdings

## Overview

Laboratory Corporation of America Holdings (Labcorp) is a global healthcare and life-sciences company providing clinical laboratory testing and laboratory services for pharmaceutical and biotechnology research and drug development. It operates through Diagnostics Laboratories, which provides routine and specialty testing, and Biopharma Laboratory Services, which supports drug development and clinical trials. [1](https://app.finbar.com/go?id=P85146029)[2](https://app.finbar.com/go?id=P59673546)[3](https://app.finbar.com/go?id=P97237671)

Labcorp’s diagnostics business is concentrated in the United States and Canada, while its biopharma services support customers and clinical trials worldwide. The company states its mission is “to improve health and improve lives.” [2](https://app.finbar.com/go?id=P59673546)[4](https://app.finbar.com/go?id=P46304834)[5](https://www.labcorp.com/about)

For fiscal year 2025, Labcorp reported revenue of approximately $13.95 billion. It had nearly 71,000 employees and served clients in approximately 100 countries. [2](https://app.finbar.com/go?id=P59673546)[1](https://app.finbar.com/go?id=P85146029)
[1](https://app.finbar.com/go?id=P85146029)[2](https://app.finbar.com/go?id=P59673546)[3](https://app.finbar.com/go?id=P97237671)[4](https://app.finbar.com/go?id=P46304834)[5](https://www.labcorp.com/about)

## Products & services

Labcorp’s Diagnostics segment offers routine clinical tests, including clinical chemistry, urinalysis, blood counts, thyroid, PAP, A1C, PSA, infectious-disease, vitamin D, microbiology and substance testing. Specialty and esoteric services include anatomic pathology and oncology, cardiovascular and coagulation testing, diagnostic genetics, endocrinology, women’s health, pharmacogenetics, occupational testing and drug monitoring, as well as chronic-disease programs and kidney-stone prevention. Services also include health-fair, workplace and at-home testing, vaccinations and screening. Labcorp reported launching more than 130 tests in 2025, including Alzheimer’s diagnostic, molecular residual disease and oncology-precision tests. [6](https://app.finbar.com/go?id=T4728755)[7](https://app.finbar.com/go?id=T3342666)

Its diagnostic capabilities include digital pathology slide review and sharing, provider and payer portals, and patient tools for appointments, check-in, results and account management. Labcorp reports more than 90,000 electronic interfaces, with most results available within one to two days; named digital tools include Test Finder, a generative-AI test-selection tool integrated with Labcorp Diagnostic Assistant™. [7](https://app.finbar.com/go?id=T3342666)[8](https://app.finbar.com/go?id=T2720115)

Biopharma Laboratory Services include early-development research and central laboratory services. Early-development offerings cover lead optimization, bioanalytical testing, general, genetic and immunotoxicology, nonclinical pathology, safety pharmacology, respiratory and developmental and reproductive toxicology studies, biologics assessments and early-phase development support. Central-lab services for clinical trials include testing, specimen logistics and tracking, pre-analytical processing, storage and shipment, biorepository services, submission-ready data, and trial access and recruitment support. Labcorp Global Trial Connect supports study start-up, supply management, site workflows and sample visibility. [9](https://app.finbar.com/go?id=T6518048)[8](https://app.finbar.com/go?id=T2720115)

For the six months ended June 30, 2026, Diagnostics generated $5,662.8 million and Biopharma Laboratory Services $1,616.8 million of segment revenue, against consolidated revenue of $7,268.7 million after eliminations and other; these amounts correspond to roughly 77.9% and 22.2% of consolidated revenue, respectively, before rounding. The 2025 annual report described the business mix as 78% Diagnostics and 22% Biopharma Laboratory Services. [10](https://app.finbar.com/go?id=T16832939)[9](https://app.finbar.com/go?id=T6518048)
[6](https://app.finbar.com/go?id=T4728755)[7](https://app.finbar.com/go?id=T3342666)[8](https://app.finbar.com/go?id=T2720115)[9](https://app.finbar.com/go?id=T6518048)[10](https://app.finbar.com/go?id=T16832939)

## Geographic presence

In FY2025, Labcorp reported revenue across three regions: 87% from North America, 9% from Europe, and 4% from Other. The disclosure does not separately identify U.S. revenue or the countries included in “Other.” [11](https://app.finbar.com/go?id=T10934724)[12](https://www.sec.gov/Archives/edgar/data/920148/000092014826000111/lh-20251231.htm)

The company reported nearly 71,000 employees serving clients in approximately 100 countries, with employees located across 17 countries; it did not provide a country-by-country employee breakdown. [1](https://app.finbar.com/go?id=P85146029)[13](https://app.finbar.com/go?id=P29960772) Labcorp’s global-reach page lists more than 2,200 U.S. patient service centers, more than 30 U.S. reference and specialty labs, and more than 75 global labs. These facility counts are not specified as FY2025 figures. [14](https://www.labcorp.com/about/our-story/global-reach)
[11](https://app.finbar.com/go?id=T10934724)[1](https://app.finbar.com/go?id=P85146029)[13](https://app.finbar.com/go?id=P29960772)[12](https://www.sec.gov/Archives/edgar/data/920148/000092014826000111/lh-20251231.htm)[14](https://www.labcorp.com/about/our-story/global-reach)

## Business segments

For the fiscal year ended December 31, 2025, Labcorp reported two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). Dx provides routine and specialty clinical laboratory testing, including anatomic pathology and genetic and genomic testing; its specialty areas include oncology, cardiovascular, coagulation, infectious disease and women’s health. [2](https://app.finbar.com/go?id=P59673546)[3](https://app.finbar.com/go?id=P97237671)[15](https://app.finbar.com/go?id=P66399904) BLS serves pharmaceutical, biotechnology and diagnostic companies through its Central Laboratory and Early Development businesses, supporting clinical trials with laboratory testing, specimen and data services, as well as early-development research and bioanalysis. [16](https://app.finbar.com/go?id=P84480021)

By 2025 revenue, Dx contributed approximately 78.0% ($10,876.5 million) and BLS approximately 22.2% ($3,098.2 million), calculated against consolidated revenue of $13,951.7 million. [17](https://app.finbar.com/go?id=T602633) The reported segment revenues include intercompany eliminations, so the rounded percentages do not sum to exactly 100%. The 2024 annual filing also reported Dx and BLS as the two segments. [18](https://app.finbar.com/go?id=P110767716)
[2](https://app.finbar.com/go?id=P59673546)[3](https://app.finbar.com/go?id=P97237671)[15](https://app.finbar.com/go?id=P66399904)[16](https://app.finbar.com/go?id=P84480021)[17](https://app.finbar.com/go?id=T602633)[17](https://app.finbar.com/go?id=T602633)[17](https://app.finbar.com/go?id=T602633)[18](https://app.finbar.com/go?id=P110767716)

## Company history

Laboratory Corporation of America Holdings traces its origins to two predecessor businesses. Biomedical Laboratories, founded in Burlington, North Carolina, in 1969, became Roche Biomedical Laboratories after Hoffmann-La Roche acquired it in 1982. Another predecessor, National Health Laboratories, was incorporated in 1971 and adopted that name in 1974. [19](https://www.labcorp.com/about/our-story/history) [20](https://www.sec.gov/Archives/edgar/data/832427/0000832427-94-000010.txt)

National Health Laboratories and Roche Biomedical Laboratories merged in 1995 to form Laboratory Corporation of America Holdings. The company expanded its testing operations through acquisitions including National Genetics Institute in 2000, Dynacare in 2002, and DIANON Systems in 2003. [19](https://www.labcorp.com/about/our-story/history) [21](https://ir.labcorp.com/news-releases/news-release-details/laboratory-corporation-americar-completes-acquisition-ofnational) [22](https://ir.labcorp.com/news-releases/news-release-details/labcorpr-completes-acquisition-dynacare-inc) [23](https://www.labcorp.com/education-events/press-releases/labcorpr-completes-acquisition-dianon-systems-inc)

In 2015, Labcorp completed its acquisition of Covance, combining clinical laboratory testing with drug-development services. It later spun off its clinical development business as Fortrea in 2023. In 2024, a holding-company reorganization made Labcorp Holdings Inc. the public parent, with Laboratory Corporation of America Holdings as its wholly owned subsidiary. [24](https://ir.labcorp.com/news-releases/news-release-details/labcorp-completes-acquisition-covance) [25](https://ir.labcorp.com/news-releases/news-release-details/labcorp-completes-spin-fortrea) [26](https://www.sec.gov/Archives/edgar/data/920148/000092014824000063/lh-20240517.htm)
[19](https://www.labcorp.com/about/our-story/history)[20](https://www.sec.gov/Archives/edgar/data/832427/0000832427-94-000010.txt)[21](https://ir.labcorp.com/news-releases/news-release-details/laboratory-corporation-americar-completes-acquisition-ofnational)[22](https://ir.labcorp.com/news-releases/news-release-details/labcorpr-completes-acquisition-dynacare-inc)[23](https://www.labcorp.com/education-events/press-releases/labcorpr-completes-acquisition-dianon-systems-inc)[24](https://ir.labcorp.com/news-releases/news-release-details/labcorp-completes-acquisition-covance)[25](https://ir.labcorp.com/news-releases/news-release-details/labcorp-completes-spin-fortrea)[26](https://www.sec.gov/Archives/edgar/data/920148/000092014824000063/lh-20240517.htm)

## Sources

1. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=P85146029)
2. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=P59673546)
3. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=P97237671)
4. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=P46304834)
5. [www.labcorp.com](https://www.labcorp.com/about)
6. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=T4728755)
7. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=T3342666)
8. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=T2720115)
9. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=T6518048)
10. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16832939)
11. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=T10934724)
12. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/920148/000092014826000111/lh-20251231.htm)
13. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=P29960772)
14. [www.labcorp.com](https://www.labcorp.com/about/our-story/global-reach)
15. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=P66399904)
16. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=P84480021)
17. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2025 Y)](https://app.finbar.com/go?id=T602633)
18. [LABORATORY CORP OF AMERICA HOLDINGS — Full financial report (2024 Y)](https://app.finbar.com/go?id=P110767716)
19. [www.labcorp.com](https://www.labcorp.com/about/our-story/history)
20. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/832427/0000832427-94-000010.txt)
21. [ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/laboratory-corporation-americar-completes-acquisition-ofnational)
22. [ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorpr-completes-acquisition-dynacare-inc)
23. [www.labcorp.com](https://www.labcorp.com/education-events/press-releases/labcorpr-completes-acquisition-dianon-systems-inc)
24. [ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-completes-acquisition-covance)
25. [ir.labcorp.com](https://ir.labcorp.com/news-releases/news-release-details/labcorp-completes-spin-fortrea)
26. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/920148/000092014824000063/lh-20240517.htm)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.